ARCH Venture Management, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), ARCH Venture Management, LLC reported 9 stock positions worth $230.2 million. Its top holding was Beam Therapeutics (BEAM) at 48.9% of the portfolio, followed by Rapport Therapeutics (RAPP, 28.7%) and Erasca (ERAS, 12.1%). Compared with Q3 2024, it added to 1 and reduced 1. The biggest buy was Cero Therapeutics (shares +550%) and the biggest sale Beam Therapeutics (BEAM, shares −6%).
- Most Recent 13F
- Q2 2026
- Location
- CHICAGO, IL
- CIK
- 0001274403
- Portfolio Value
- $230.2M (Q4 2024)
- SEC Filing
- 0001012975-25-000089 ↗ filed Feb 14, 2025
Holdings Value
Holdings 9 stocks · $230.2M
| BEAM Beam Therapeutics Inc. | 48.91% | 4,540,132 | $112.6M | Reduce -6.1% |
| RAPP Rapport Therapeutics Inc. | 28.73% | 3,728,738 | $66.1M | No change |
| ERAS Erasca Inc. | 12.05% | 11,055,554 | $27.7M | No change |
| VERV Verve Therapeutics Inc. | 4.92% | 2,008,809 | $11.3M | No change |
| GOSS Gossamer Bio Inc. | 3.17% | 8,055,916 | $7.3M | No change |
| OMIC Singular Genomics Systems Inc. | 1.07% | 126,630 | $2.5M | No change |
| QTTB Q32 Bio Inc. | 0.48% | 320,482 | $1.1M | No change |
| UNBX Unity Biotechnology Inc. | 0.43% | 1,004,817 | $981K | No change |
| CERO THERAPEUTICS HLDGS INC | 0.24% | 9,393,561 | $564K | Add +550.4% |
Portfolio Sells Q3 2024 → Q4 2024
| BEAM Beam Therapeutics Inc. | Reduce -6.1% | 48.91% | +3.45 |
Portfolio Buys Q3 2024 → Q4 2024
| CERO THERAPEUTICS HLDGS INC | Add +550.4% | 0.24% | +0.19 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.1B | PBLS, BEAM, RAPP, SPTX, ERAS |
| Q1 2026 | 10 | $677.1M | MAZE, RAPP, VIR, ERAS, BEAM |
| Q4 2025 | 9 | $651.7M | MAZE, BEAM, RAPP, LYEL, VIR |
| Q3 2025 | 9 | $492.4M | RAPP, BEAM, MAZE, VIR, LYEL |
| Q2 2025 | 11 | $299.1M | BEAM, VIR, MAZE, RAPP, VERV |
| Q1 2025 | 9 | $206.2M | BEAM, MAZE, RAPP, ERAS, VERV |
| Q4 2024 | 9 | $230.2M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q3 2024 | 9 | $260.6M | BEAM, RAPP, ERAS, QTTB, VERV |
| Q2 2024 | 9 | $266.0M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q1 2024 | 8 | $80.3M | VERV, ERAS, GOSS, DNLI, QTTB |